Ann: Douglas Cubbin appointed as Incoming Chairman of OncoSil, page-34

I think the answers to all our questions are with Kidder Williams.

I'm encouraged by the fact they took us on. They are usually great at their job.

Bought a few more last week, on the basis that KW is working on it and someone wanted out of 16 million shares.

I still think there is around 150 million+ worth of value in the assets of the company. Aside from the product itself, there's the CE Mark, the current RCTs, a really good management team and a HDE proposal in front of FDA. There is even the start of revenue. These are all valuable assets. There are lots of biomedtech companies valued much higher that can only hope of achieving some of those milestones.

I'd say something will need to emerge by the AGM at the latest.